{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:04:36Z","timestamp":1783951476153,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,13]]},"DOI":"10.7759\/cureus.112577","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:07:08Z","timestamp":1783948028000},"source":"Crossref","is-referenced-by-count":0,"title":["Regulatory Perspectives in Precision Oncology: Challenges and Opportunities for Tyrosine Receptor Kinase (NTRK) Inhibitors in Non-small Cell Lung Cancer (NSCLC)"],"prefix":"10.7759","author":[{"given":"Justin","family":"Gainor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Bundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon JP","year":"2020","unstructured":"Solomon JP, Linkov I, Rosado A, et al.. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020, 33:38-46. 10.1038\/s41379-019-0324-7","journal-title":"Mod Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9109","article-title":"Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer","volume":"42","author":"Drilon AE","year":"2024","unstructured":"Drilon AE, Kummar S, Lin JJ, et al.. Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer. J Clin Oncol. 2024, 42:8570. 10.1200\/JCO.2021.39.15_suppl.9109","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107442","article-title":"Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer","volume":"188","author":"Cho BC","year":"2024","unstructured":"Cho BC, Chiu CH, Massarelli E, et al.. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer. 2024, 188:107442. 10.1016\/j.lungcan.2023.107442","journal-title":"Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04079-7","article-title":"Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse B","year":"2026","unstructured":"Besse B, Lin JJ, Bazhenova L, et al.. Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1\/2 trial. Nat Med. 2026, 32:682-9. 10.1038\/s41591-025-04079-7","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al.. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018, 378:731-9. 10.1056\/NEJMoa1714448","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele RC","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, et al.. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020, 21:271-82. 10.1016\/S1470-2045(19)30691-6","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2023.0471","article-title":"Current therapeutic landscape and resistance mechanisms to larotrectinib","volume":"20","author":"Xie W","year":"2024","unstructured":"Xie W, Xu J, Lu S, Zhang Y. Current therapeutic landscape and resistance mechanisms to larotrectinib. Cancer Biol Med. 2024, 20:967-71. 10.20892\/j.issn.2095-3941.2023.0471","journal-title":"Cancer Biol Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35085","article-title":"Revolutionizing cancer drug development: harnessing the potential of basket trials","volume":"130","author":"Subbiah V","year":"2024","unstructured":"Subbiah V, Burris HA 3rd, Kurzrock R. Revolutionizing cancer drug development: harnessing the potential of basket trials. Cancer. 2024, 130:186-200. 10.1002\/cncr.35085","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21600","article-title":"An overview of precision oncology basket and umbrella trials for clinicians","volume":"70","author":"Park JJ","year":"2020","unstructured":"Park JJ, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020, 70:125-37. 10.3322\/caac.21600","journal-title":"CA Cancer J Clin"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.893400","article-title":"A comparison of post-marketing measures imposed by regulatory agencies to confirm the tissue-agnostic approach","volume":"9","author":"Mulder J","year":"2022","unstructured":"Mulder J, van Stuijvenberg OC, van Hennik PB, Voest EE, Pasmooij AM, Stoyanova-Beninska V, de Boer A. A comparison of post-marketing measures imposed by regulatory agencies to confirm the tissue-agnostic approach. Front Med (Lausanne). 2022, 9:893400. 10.3389\/fmed.2022.893400","journal-title":"Front Med (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00701-X","article-title":"From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit","volume":"24","author":"Lythgoe MP","year":"2023","unstructured":"Lythgoe MP, Krell J, Bower M, et al.. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. Lancet Oncol. 2023, 24:e150-60. 10.1016\/S1470-2045(22)00701-X","journal-title":"Lancet Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3292","article-title":"Project Orbis: global collaborative review program","volume":"26","author":"de Claro RA","year":"2020","unstructured":"de Claro RA, Spillman D, Hotaki LT, et al.. Project Orbis: global collaborative review program. Clin Cancer Res. 2020, 26:6412-6. 10.1158\/1078-0432.CCR-20-3292","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2 C","year":"2019","unstructured":"Marchi\u00f2 C, Scaltriti M, Ladanyi M, et al.. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019, 30:1417-27. 10.1093\/annonc\/mdz204","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz384","article-title":"Identifying patients with NTRK fusion cancer","volume":"30","author":"Solomon JP","year":"2019","unstructured":"Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019, 30:viii16-22. 10.1093\/annonc\/mdz384","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/489408-regulatory-perspectives-in-precision-oncology-challenges-and-opportunities-for-tyrosine-receptor-kinase-ntrk-inhibitors-in-non-small-cell-lung-cancer-nsclc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:07:09Z","timestamp":1783948029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/489408-regulatory-perspectives-in-precision-oncology-challenges-and-opportunities-for-tyrosine-receptor-kinase-ntrk-inhibitors-in-non-small-cell-lung-cancer-nsclc"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.112577","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}